MADRID — New data from two randomized trials suggest that dual antiplatelet therapy (DAPT) should be significantly shortened or not used at all after coronary artery bypass surgery (CABG). Researchers ...
Compared with ticagrelor or aspirin alone, 12 months of dual antiplatelet therapy (DAPT) after coronary artery bypass graft surgery is associated with a reduced risk of MACE that persists out to 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback